Submitted September 21, 2018 - USP Comment Letter to FDA in additional to USP's oral testimony on September 4, 2021 on competition and innovation in the biological products marketplace, including facilitating greater availability of biosimilar and interchangeable products. Docket No. FDA-2018-N-2689.
